069620.KS
Daewoong pharmaceutical Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 114,800.00
−7.49%Year over year
Reported trailing growth
- Revenue
- +9.9%
- EBITDA
- +45.1%
- EBIT
- +10.4%
- EPS
- +160.3%
- Free cash flow
- -47.5%
- Operating cash flow
- +68.7%
Forward estimates
Based on analyst estimates
- Revenue
- +0.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +7.1%
- EBITDA
- +42.4%
- EBIT
- +26.8%
- Net income
- +66.8%
- EPS
- +64.6%
- Free cash flow
- +76.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026